Relamorelin

DB12678InvestigationalSmall molecule

Relamorelin has been investigated for the treatment and basic science of Gastroparesis, Gastric Motility, Diabetes Mellitus, Parkinson's Disease, and Chronic Constipation, among others.

Mechanism: Pharmacologically active on Growth hormone secretagogue receptor type 1
Curator reviewed
Formula / weight: C₄₃H₅₀N₈O₅S · 790.98 g/mol (avg)
Code names: BIM-28131

Resolves to

Compound

UNIIBIW199E18VCAS661472-41-9PubChem44251769

Structure

InChIKeyKUBPNVYPKPWGRJ-LIVOIKKVSA-NSMILESNC(=O)C1(CCNCC1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@@H](CC1=CSC2=CC=CC=C12)NC(=O)C1CCNCC1

Targets

Q92847GHSR

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Relamorelin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account